Adverse events146

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 146

Type	Event	Organ system	Group	Affected	At risk
other	Alanine aminotransferase increased	Investigations	Crizotinib Oral Capsule [Xalkori] Monotherapy	4	6
other	Alanine aminotransferase increased	Investigations	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	17	27
other	Aspartate aminotransferase increased	Investigations	Crizotinib Oral Capsule [Xalkori] Monotherapy	4	6
other	Aspartate aminotransferase increased	Investigations	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	20	27
other	Abdominal pain	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Abdominal pain	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	8	27
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Crizotinib Oral Capsule [Xalkori] Monotherapy	3	6
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	2	27
other	Constipation	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Constipation	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	10	27
other	Gastrointestinal pain	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Gastrointestinal pain	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	2	27
other	Vomiting	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Vomiting	Gastrointestinal disorders	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	16	27
other	Edema trunk	General disorders	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Edema trunk	General disorders	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	0	27
other	Creatinine increased	Investigations	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Creatinine increased	Investigations	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	4	27
other	Lymphocyte count decreased	Investigations	Crizotinib Oral Capsule [Xalkori] Monotherapy	2	6
other	Lymphocyte count decreased	Investigations	Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection	4	27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03620643/events

API reference For AI assistants

Adverse events146

Sources 3

Read this list from software.